Document #72 Medical Affairs
Source: url • Audience: medical_affairs • Status: completed
Routing confidence: 90% • Candidates: Medical Affairs, R&D, Commercial
Routing reasons: ML fallback: low confidence (56% < 57%); The document discusses non-alcoholic steatohepatitis (NASH) and its worsening in obese patients, focusing on medical research findings.; It includes detailed scientific data on biochemical pathways, lipidomics, and translational research linking obesity to liver disease progression.; Authored and reviewed by medical professionals and scientists from a medical university, it is targeted toward healthcare and medical research professionals involved in disease understanding and treatment development.; The content is oriented toward understanding disease mechanisms which supports medical affairs functions like scientific communication and education around medical evidence.
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough ...
Show full document
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breastfeeding Cold, Flu & Cough Dermatology Diabetes Eating Disorders Eye Health Gastrointestinal Health Heart Disease Lung Cancer Mental Health Parkinson's Disease Pregnancy Sleep Urology View Health A-Z × Top Health Categories Coronavirus Disease COVID-19 Eating Disorders Diet & Nutrition Eye Health Artificial Intelligence Gastrointestinal Health Allergies Heart Disease Alzheimer's & Dementia Lung Cancer Arthritis & Rheumatology Mental Health Breast Cancer Parkinson's Disease Breastfeeding Pregnancy Cold, Flu & Cough Sleep Dermatology Urology Diabetes View Health A-Z Medical Home Life Sciences Home About News Life Sciences A-Z White Papers Lab Equipment Interviews Newsletters Webinars More... eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member White Papers MediKnowledge eBooks Posters Podcasts Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Webinars eBooks Posters Podcasts Contact Meet the Team Advertise Search Become a Member Scientists reveal why non-alcoholic steatohepatitis worsens in obese people Download PDF Copy Reviewed Medical University of South Carolina Jan 20 2016 In results published on October 19, 2015 in the Journal of Lipid Research , a team of translational scientists at the Medical University of South Carolina (MUSC) report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese. The results may help prevent cirrhosis and liver cancer, according to co-senior authors Kenneth D. Chavin, M.D., PhD, a transplant surgeon in the MUSC Health Department of Surgery, and Lauren Ashley Cowart, PhD, Associate Professor of Biochemistry and Co-Director of the MUSC Center of Biomedical Research Excellence in Lipidomics and Pathobiology. NASH (also called non-alcoholic fatty liver disease ) has become a major cause of liver disease requiring transplant. "In my 17 years of doing liver transplants, it's gone from 4% of patients to around 20% of patients who get transplants because of NASH," says Chavin. "In 10-15 years, because of advances with Hepatitis C, it will probably become the number one reason why patients get transplants." When excess dietary fats are consumed over time, fat deposits form in the liver and NASH can develop. Early-stage NASH is typically not associated with any physical symptoms; nearly 30% of people in the U.S. have it. Though obesity is correlated with the development of NASH, the team wanted to know exactly why NASH worsens to a stage requiring transplant in certain obese people. "Obesity doesn't cause disease in every obese person and we don't understand why it does in some but not others," explains Cowart. The team suspected that inflammation stemming from a lipid molecule called sphingosine-1-phosphate (S1P) might be responsible. They'd previously discovered in other organs that S1P is increased by excess dietary saturated fat. Related Stories Nearly half of adults now live with heart disease as obesity and diabetes surge Genetic study establishes causal link between obesity and cognitive decline Study identifies genes, smoking, and obesity as pneumonia risk factors Chavin took biopsies from human livers during transplant surgery and supplied them to Cowart, who determined the levels of sphingosine kinase 1, the enzyme that makes S1P. They found double the normal amount of sphingosine kinase 1 in livers of obese people with non-alcoholic steatohepatitis. The team wanted more understanding of why S1P causes inflammation, but NASH has previously been difficult to mimic in the laboratory setting. They developed a new and highly improved preclinical model of NASH, wherein mice were fed on custom-designed diets of either high saturated fat or high unsaturated fat. Curiously, mice on each type of diet became obese, but only mice on the saturated fat diet developed inflammation and NASH-like pathology stemming from S1P. Taking the human and pre-clinical studies together, it's likely that saturated fat, but not unsaturated fat, raises S1P levels in obese people, and it's S1P that unleashes the inflammation that characterizes NASH. Performing lipid studies in the laboratory is not easy--most biochemistry is water-based, and fat and water don't easily mix. The group relied on the MUSC Sphingolipidomics Core laboratory, one of only a handful of such facilities in the country capable of developing the new methods needed to examine S1P for their study. "Without lipidomics, we never would have understood that saturated fats activate this pathway," says Cowart. The team is working to identify the S1P receptors responsible for inflammation in NASH, with the ultimate goal of designing treatments to prevent the need for a liver transplant in obese patients with NASH. Does this work support the idea that it's the type of fat, but not all fat, that leads to health problems? After all, mice fed a high unsaturated fat diet still became obese but were metabolically healthy. "Because the unsaturated fat diet didn't cause NASH, it may provide a clue as to what actually links obesity to disease," says Cowart. "Even if it's difficult to lose weight, dietary modifications might prevent some disease associated with obesity." Source: Medical University of South Carolina Posted in: Medical Science News | Medical Research News | Medical Condition News Comments (0) Download PDF Copy Suggested Reading Obesity drives shared genetic risk behind many chronic disease combinations Screen time may increase body fat in children Obesity drives one in ten infectious disease deaths Research shows the effect of losing weight in preventing multiple diseases Low-grade inflammation connects aging, obesity and cognitive impairment Breastfeeding and healthy infant diets may help lower obesity risk by age nine Eating melatonin-rich foods is linked to lower obesity and depression rates Addressing unsustainable food systems can deliver double benefits for health and climate Comments The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical. Cancel reply to comment Post a new comment Login (Logout) Quirky Comment Title Post Sign in to keep reading We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free. Sign in with Google Sign in with Apple Sign in with LinkedIn Sign in with Facebook or Sign in with email Trending Stories Latest Interviews Top Health Articles Case report examines potential cancer risks after mRNA vaccination Study uncovers immune trigger behind vaccine-induced immune thrombocytopenia and thrombosis Nasal COVID vaccine boost increases IgA responses linked to variant neutralisation Researchers identify a previously unknown cellular barrier in the brain Ozempic users continue treatment when weight loss works despite side effects Advancing brain microphysiological systems (bMPS) Dr. Lena Smirnova Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced disease modeling. PhD researcher at LifeArc Natasha Bury Targeted protein degradation presents a promising strategy to address antimicrobial resistance, focusing on innovative approaches for gram-negative bacteria. Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research Rosanna Zhang In our latest interview, News-Medical speaks with Rosanna Zhang from ACROBiosystems about utilizing organoids for disease modeling in the field of neuroscience research. Astaxanthin and Human Health: Evidence on Skin, Vision, Brain, and Aging The Gut–Brain–Skin Axis: How Diet and Gut Health Influence Mood, Skin, and Aging How Morning Routines Influence Cognitive Performance, Mood, and Circadian Rhythm Camel Milk Nutrition Facts and Potential Health Benefits Explained Edible Insects as Food: Nutritional Benefits, Safety, and Environmental Impact Latest News Researchers discover a way to breach cancer’s impenetrable fortress Weekend holiday rehabilitation supports recovery in elderly hip fracture patients Novel implant delivers tiny growth-promoting particles directly to injured nerve cells Changes in lymphatic vessels can help identify aggressive oral cancer at an early stage Axol Bioscience acquires ophthalmology business from Newcells Biotech Newsletters you may be interested in Laboratory Diagnostics ( Subscribe or Preview ) Hepatology ( Subscribe or Preview ) Infectious Diseases ( Subscribe or Preview ) See all Newsletters » High Credibility: This website adheres to all nine standards of credibility and transparency. Medical Links Medical Home Functional Food News Health A-Z White Papers Thought Leaders Insights MediKnowledge Series Health & Personal Care Medical Devices Drugs eBooks Posters Podcasts Life Sciences Links Life Sciences Home News Lab Instruments & Equipment Life Sciences A-Z White Papers Thought Leaders Insights Webinars eBooks Posters Podcasts Other Useful Links About Meet the Team Search Newsletters Sitemap Advertise Contact Terms & Conditions Privacy & Cookie Policy Content Policy Ownership & Funding Information Other AZoNetwork Sites AZoM AZoNano AZoCleantech AZoOptics AZoRobotics AZoSensors AZoMining AZoQuantum AZoBuild AZoLifeSciences AZoAi Facebook Twitter LinkedIn News-Medical.Net provides this medical information service in accordance with these terms and conditions . Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide. Update Your Privacy Preferences Last Updated: Wednesday 18 Feb 2026 News-Medical.net - An AZoNetwork Site Owned and operated by AZoNetwork, © 2000-2026 Azthena logo with the word Azthena Maximise chat window Hide chat window Your AI Powered Scientific Assistant Hi, I'm Azthena, you can trust me to find commercial scientific answers from News-Medical.net. To start a conversation, please log into your AZoProfile account first, or create a new account. Registered members can chat with Azthena, request quotations, download pdf's, brochures and subscribe to our related newsletter content . Log in A few things you need to know before we start. Please read and accept to continue. Use of “Azthena” is subject to the terms and conditions of use as set out by OpenAI . Content provided on any AZoNetwork sites are subject to the site Terms & Conditions and Privacy Policy . Large Language Models can make mistakes. Consider checking important information. I understand, and agree to receive occasional emails about Azthena such as usage tips and new feature announcements. Please check the box above to proceed. Start Chat Great. Ask your question. Clear Chat Clear Chat Brief Moderate Detailed Azthena may occasionally provide inaccurate responses. Read the full terms . Terms While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided. Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles. Please do not ask questions that use sensitive or confidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Obesity sharply increases hospitalisation risk from infections, global analysis shows
One-line Summary
Saturated fat increases sphingosine-1-phosphate (S1P) levels in obese individuals, driving inflammation and progression of non-alcoholic steatohepatitis (NASH), unlike unsaturated fat.
Decision Bullets
Expected: 3–5 bullets.
- Scientific Summary: S1P synthesized via sphingosine kinase 1 is elevated by saturated fats and promotes liver inflammation driving NASH in obese patients.
- Evidence Gaps: Precise identification of S1P receptors mediating inflammation remains incomplete, limiting targeted therapeutic design.
- Medical Insights: Differentiating fat types in diet interventions may reduce NASH incidence despite persistent obesity.
- Stakeholder Considerations: Patients, clinicians, and researchers should prioritize lipid type over weight alone in managing NASH risk.
- Next Steps: Focus on elucidating S1P receptor pathways and developing S1P-targeted therapies to prevent progression to liver transplant.
Mind Map
mindmap
root((NASH in Obese))
Causes
Dietary Fat
Saturated Fat --> Increases S1P
Unsaturated Fat --> Obesity without NASH
Mechanism
Sphingosine Kinase 1 --> Produces S1P
S1P --> Inflammation --> NASH Progression
Evidence
Human Liver Biopsies --> Elevated kinase in obese NASH
Mouse Models --> Saturated fat diet induces NASH
Gaps
Unknown S1P Receptors
Outcomes
NASH --> Cirrhosis & Liver Cancer
Need for Liver Transplant
Future Directions
Identify S1P Receptors
Develop Targeted Therapies
Dietary Modification Emphasis
If needed, use the in-page "View source" button on the job detail page to see the raw mind map.
Tags
- nash
- liver disease
- obesity
- sphingosine-1-phosphate
- saturated fat
- lipidomics
- inflammation
Key Clues
- NASH progression linked to lipid molecule S1P
- Sphingosine kinase 1 doubled in obese NASH patients
- Saturated fat diet induced inflammation in mice
- Unsaturated fat caused obesity without NASH
- MUSC developed advanced lipidomic techniques
Tag Intelligence
Domain: Clinical & Medical Strategy
Canonical tags
- nash
- obesity
- sphingosine-1-phosphate
- liver disease
- saturated fat
- lipidomics
- inflammation
Tool Summary
Citations: 4
Scientific Summary: S1P synthesized via sphingosine kinase 1 is elevated by saturated fats and promotes liver inflammation driving NASH in obese patients.
The team is working to identify the S1P receptors responsible for inflammation in NASH, with the ultimate goal of designing treatments to prevent the need for a liver transplant in obese patients with NASH.
…heir study. "Without lipidomics, we never would have understood that saturated fats activate this pathway," says Cowart. The team is working to identify the S1P receptors responsible for inflammation in NASH, with the ultimate goal of designing treatments to prevent the need for a liver transplant in obese patients with NASH . Does this work support the idea that it's the type of fat, but not all fat, that leads to health problems? After all, …
Medical Insights: Differentiating fat types in diet interventions may reduce NASH incidence despite persistent obesity.
"Because the unsaturated fat diet didn't cause NASH, it may provide a clue as to what actually links obesity to disease," says Cowart.
…s to health problems? After all, mice fed a high unsaturated fat diet still became obese but were metabolically healthy. "Because the unsaturated fat diet didn't cause NASH, it may provide a clue as to what actually links obesity to disease," says Cowart . "Even if it's difficult to lose weight, dietary modifications might prevent some disease associated with obesity." Sou…
Next Steps: Focus on elucidating S1P receptor pathways and developing S1P-targeted therapies to prevent progression to liver transplant.
The team is working to identify the S1P receptors responsible for inflammation in NASH, with the ultimate goal of designing treatments to prevent the need for a liver transplant in obese patients with NASH.
…heir study. "Without lipidomics, we never would have understood that saturated fats activate this pathway," says Cowart. The team is working to identify the S1P receptors responsible for inflammation in NASH, with the ultimate goal of designing treatments to prevent the need for a liver transplant in obese patients with NASH . Does this work support the idea that it's the type of fat, but not all fat, that leads to health problems? After all, …
Risk flags: 2 High · 0 Medium · 0 Low
High severity risk detected.
Related Documents
Audience: R&D
Study calls for new gold standard in research to treat non-alcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search
Overlap: liver disease, nash
Audience: Medical Affairs
Potential leptin therapy for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences
Overlap: liver disease, nash
Audience: Medical Affairs
Discovery could pave the way for developing therapies to treat nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member
Overlap: nash, obesity
Audience: R&D
Researchers find possible genetic basis and mouse model for nonalcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member Se
Overlap: liver disease, nash
Audience: Medical Affairs
A new, potential treatment for nonalcoholic steatohepatitis with fibrosis Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Ho
Overlap: nash
Audience: Medical Affairs
Auto-aggressive immune cells cause liver immune pathology in non-alcoholic steatohepatitis Skip to content Menu Medical Home Life Sciences Home Become a Member
Overlap: nash
Audience: Commercial
Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis August 19, 2025
Overlap: liver disease
Audience: Medical Affairs
FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA Skip to main content Skip to FDA Search Skip to in this section m
Overlap: nash
Audience: Medical Affairs
CePA: Novel nanomedicine for alleviating MASH via mTOR repression Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life
Overlap: inflammation
Audience: Commercial
Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited July 30, 2025 P
Overlap: liver disease